(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Former biotech CEO sued over COVID vaccine alleged insider trading - 2Most loved Fish Dish: What's Your Sea Pleasure?
- 3The Solution to Individual budget: Dominating Cash The board
- 4Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
- 5Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices
- Nature's Best: A Manual for Beautiful Train Rides
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Startled Venezuelans express relief but also fear after Maduro arrest
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- Sixteen Kenyans missing in Russia after army recruitment
- How mountain terraces have helped Indigenous peoples live with climate uncertainty
- Ocean side Locations for a Family Excursion
- A Manual for Nations with Extraordinary Food
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
